Mikael Dolsten Net Worth

The estimated Net Worth of Mikael Dolsten is at least $53.2 Milione dollars as of 7 November 2022. Mikael Dolsten owns over 79,108 units of Pfizer stock worth over $12,457,408 and over the last 12 years he sold PFE stock worth over $31,176,890. In addition, he makes $9,598,040 as Chief Scientific Officer, President - Worldwide Research e Development and Medical at Pfizer.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mikael Dolsten PFE stock SEC Form 4 insiders trading

Mikael has made over 26 trades of the Pfizer stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 79,108 units of PFE stock worth $2,627,177 on 7 November 2022.

The largest trade he's ever made was exercising 218,447 units of Pfizer stock on 23 February 2017 worth over $4,593,940. On average, Mikael trades about 27,548 units every 35 days since 2012. As of 7 November 2022 he still owns at least 420,007 units of Pfizer stock.

You can see the complete history of Mikael Dolsten stock trades at the bottom of the page.

Mikael Dolsten biography

Dr. Mikael G. Dolsten M.D., Ph.D. serves as Chief Scientific Officer, President - Worldwide Research, Development and Medical of the Company. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners from 2016 to 2017.

What is the salary of Mikael Dolsten?

As the Chief Scientific Officer, President - Worldwide Research e Development and Medical of Pfizer, the total compensation of Mikael Dolsten at Pfizer is $9,598,040. There are 2 executives at Pfizer getting paid more, with Albert Bourla having the highest compensation of $17,929,000.

How old is Mikael Dolsten?

Mikael Dolsten is 61, he's been the Chief Scientific Officer, President - Worldwide Research e Development and Medical of Pfizer since 2019. There are 9 older and 21 younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.

Insiders trading at Pfizer

Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read e James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.

What does Pfizer do?

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Complete history of Mikael Dolsten stock trades at Karyopharm Therapeutics Inc, Agilent Technologies, Pfizer e Rocket Pharmaceuticals Inc

Pfizer executives and stock owners

Pfizer executives and other stock owners filed with the SEC include:

• Albert Bourla,
  Chairman of the Board, Chief Executive Officer
• Frank D'Amelio,
  Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
• Mikael Dolsten,
  Chief Scientific Officer, President - Worldwide Research, Development and Medical
• John Young,
  Chief Business Officer, Group President
• Dr. Albert Bourla D.V.M., DVM, Ph.D.,
  Chairman & CEO
• Frank A. D'Amelio,
  CFO & Exec. VP
• Dr. Mikael Dolsten M.D., Ph.D.,
  Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
• Angela Hwang,
  Group Pres of Biopharmaceuticals Group
• John D. Young,
  Advisor
• Shantanu Narayen,
  Lead Independent Director
• Wyllie Don Cornwell,
  Independent Director
• Helen Hobbs,
  Independent Director
• Suzanne Nora Johnson,
  Independent Director
• Joseph Echevarria,
  Independent Director
• James Kilts,
  Independent Director
• Ronald Blaylock,
  Independent Director
• Dan Littman,
  Independent Director
• Scott Gottlieb,
  Independent Director
• James Quincey,
  Independent Director
• Susan Hockfield,
  Independent Director
• Susan Desmond-Hellmann,
  Director
• Gordon Loh,
  Senior Vice President, Corporate Audit
• Jennifer Damico,
  Senior Vice President, Principal Accounting Officer, Controller
• Sally Susman,
  Chief Corporate Affairs Officer, Executive Vice President
• Alexander Mackenzie,
  Executive Vice President, Chief Development Officer
• Douglas Lankler,
  Executive Vice President, General Counsel
• Rady Johnson,
  Chief Compliance, Quality and Risk Officer, Executive Vice President
• Lidia Fonseca,
  Executive Vice President, Chief Technology Officer and Digital Officer
• Dawn Rogers,
  Chief Human Resource Officer, Executive Vice President
• Angela Hwang,
  Group President, Pfizer Biopharmaceuticals Group
• Rady A. Johnson,
  Exec. VP and Chief Compliance, Quality & Risk Officer
• Douglas M. Lankler,
  Exec. VP & Gen. Counsel
• Christopher J. Stevo CFA,
  Sr. VP & Chief Investor Relations Officer
• Lidia L. Fonseca,
  Exec. VP and Chief Digital & Technology Officer
• Jennifer B. Damico,
  Sr. VP, Controller & Principal Accounting Officer
• Mike McDermott,
  Chief Financial Officer
• William Pao,
  Executive Vice President
• Stephen W Sanger,
  Director
• Frances D Fergusson,
  Director
• James C Smith,
  Director
• Laurie J Olson,
  Executive Vice President
• W Don Cornwell,
  Director
• Loretta V Cangialosi,
  Sr. Vice President, Controller
• Charles H Hill,
  Executive Vice President
• Dennis A Ausiello,
  Director
• Kirsten Lund Jurgensen,
  Executive Vice President
• Ian C Read,
  Chairman & CEO
• Freda C Lewis Hall,
  Executive Vice President
• Aamir Malik,
  Executive Vice President
• Christoffel Boshoff,
  Executive Vice President
• Michael Goettler,
  Group President
• Cyrus Taraporevala,
  Director
• Iii William H Gray,
  Director
• M Anthony Burns,
  Director
• Cavan M. Redmond,
  Group President
• Kristin C Peck,
  Executive Vice President
• David S Simmons,
  Business Unit President
• Geno J Germano,
  Business Unit President
• Anthony J Maddaluna,
  Executive Vice President
• Olivier Brandicourt,
  Business Unit President
• Marc Tessier Lavigne,
  Director
• George A Lorch,
  Director
• Amy W Schulman,
  Executive Vice President
• Constance J Horner,
  Director
• Payal Sahni,
  Executive Vice President
• William R Jr Carapezzi,
  Executive Vice President
• Michael Mc Dermott,
  Executive Vice President
• David M Denton,
  Chief Financial Officer & EVP